Inovio Pharma (INO) Misses Q2 EPS by 119c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Inovio Pharmaceuticals (INO) PT Lowered to $8 at RBC Capital
August 9, 2024 6:26 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $8.00 (from $11.00) while maintaining a Sector Perform rating.
The analyst comments "Recent and newly disclosed manufacturing issues for INO-3107's CELLECTRA device push BLA submission for accelerated approval to... More
